💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Overdose victim's father testifies in Oklahoma opioid trial of J&J

Published 05/29/2019, 12:20 PM
Updated 05/29/2019, 12:25 PM
© Reuters. Oklahoma Attorney General Mike Hunter gives an opening statement on the first day of a trial of Johnson & Johnson in Norman
TEVA
-
JNJ
-

By Nate Raymond

(Reuters) - The father of a university football player who died of a drug overdose provided emotional testimony about the personal cost of the nationwide opioid epidemic on Wednesday during the second day of trial in a lawsuit by the state of Oklahoma accusing drugmaker Johnson & Johnson (NYSE:JNJ) of fueling the crisis.

The testimony in a state court in Norman, Oklahoma, came during the first trial to result from more than 2,000 similar lawsuits against pharmaceutical manufacturers nationally seeking to hold them responsible for the opioid abuse crisis.

Those cases by state and local governments seek to hold the companies responsible for a drug abuse epidemic that the U.S. Centers for Disease Control and Prevention says led to a record 47,600 opioid-related overdose deaths in 2017.

Craig Box, an Oklahoma attorney, testified that he never suspected his son Austin was abusing prescription painkillers until after he was discovered unconscious at a friend's house in 2011 and was taken to a hospital.

Holding back tears, Box said he only learned after the death of the 22-year-old University of Oklahoma linebacker, who had a herniated disk the year before, that his son had once been prescribed opioids and must have turned to the streets to get more.

"We had no idea about the prevalence of these drugs and the dangers of these drugs," he said during testimony streamed online by Courtroom View Network.

Box was called as a witness to support claims by Oklahoma Attorney General Mike Hunter that J&J helped cause the epidemic by marketing opioids as safe and effective for everyday pain while downplaying their addictive qualities.

Hunter alleges that deceptive marketing campaigns carried out by J&J, along with OxyContin maker Purdue Pharma LP and Teva Pharmaceutical Industries (NYSE:TEVA) Ltd, led to an oversupply of addictive painkillers in the state.

Oklahoma resolved its claims against Purdue in March for $270 million and against Teva on Sunday for $85 million, leaving J&J as the only defendant in the nonjury trial before Cleveland County District Judge Thad Balkman.

J&J denies wrongdoing, arguing that its marketing efforts were proper and that the state cannot prove it caused the opioid epidemic given the role doctors, patients, pharmacists and drug dealers played.

© Reuters. Oklahoma Attorney General Mike Hunter gives an opening statement on the first day of a trial of Johnson & Johnson in Norman

The state claims that J&J's actions created an oversupply of painkillers and a public nuisance that will cost $12.7 billion to $17.5 billion to remedy over the next 20 to 30 years.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.